H.R. 5338 — what changed
Global Hope Act of 2019
From Introduced in House to Engrossed in House. 2 sections amended between Introduced in House and Engrossed in House.
2. Findings
Congress finds the following:
changed
Cancer is a leading cause of death for children and adolescents around the world, and approximately Approximately 300,000 children aged 0 to 19 years old are diagnosed with cancer each year.
The most common categories of childhood cancers include leukemia, brain cancer, lymphoma, and solid tumors, such as neuroblastoma and Wilms tumor.
Most childhood cancers can be cured with generic medicines and can be cost-effective for all income levels.
In the United States, the survival rate for children diagnosed with cancer is over 80 percent. In many developing countries, the mortality rate of children diagnosed with cancer is around 80 percent. In some parts of Africa, the mortality rate reaches 90 percent.
In September 2018, the World Health Organization announced a new effort—the Global Initiative for Childhood Cancer—with the aim of reaching at least a 60-percent survival rate for children with cancer by 2030, thereby saving an additional 1,000,000 lives.
4. Statement of policy
The United States shall seek to—
increase political commitment for childhood cancer diagnosis, treatment, and care globally;
support efforts to increase the survival rate of children with cancer globally;
support efforts to train medical personnel and develop the capabilities of other existing healthcare infrastructure to diagnose, treat, and care for childhood cancer;
improve access to affordable and essential medicines and technologies that treat childhood cancer;
elevate and prioritize efforts to reduce the mortality rate of childhood cancer in international organizations such as the United Nations;
changed
pursue research and research partnerships with international institutions to identify low-cost interventions and best practices to diagnose, treat, and care for childhood cancer in the United States and globally; and
changed
improve partnerships with international health ministries and pharmaceutical companies to facilitate efforts for broader, global clinical trials for medicines to treat or care for childhood cancer.cancer in the United States and globally.